Azenta, Inc.'s SEC filings document operating results, material events, governance matters and acquisition agreements for a life sciences solutions company built around cold-chain sample management and multiomics services. Recent Form 8-K disclosures include quarterly results and financial-condition updates, leadership and board changes, and the material definitive agreement under which Azenta UK Ltd acquired UK Biocentre.
The company’s proxy and annual-meeting filings describe director elections, advisory executive-compensation votes, equity incentive plan amendments and auditor ratification. Together with material-event reports, these filings provide formal disclosure on Azenta’s governance structure, capital-related authorizations, transaction terms and recurring public-company reporting obligations.
Azenta, Inc. reported that Interim CEO Martin D. Madaus had 1,294 common shares withheld on October 22, 2026, to satisfy tax withholding obligations arising from vesting and settlement of 3,055 restricted stock units. The transaction lists a price of $36.01 per share and left him with 41,308 common shares held directly. The footnote states this was not a market sale.
Azenta, Inc. (AZTA) approved and committed to a restructuring plan on October 5, 2026, covering its Multiomics segment. The plan includes workforce reductions and the closure of three North American Multiomics laboratory sites; Azenta began notifying affected employees on October 6, 2026. The company says the plan is intended to consolidate its laboratory network, simplify its organization and improve operating efficiency.
Azenta estimates aggregate pre-tax charges of approximately $11.0 million to $13.0 million, consisting primarily of approximately $9.0 million in asset impairment charges and approximately $3.0 million in employee severance and other restructuring charges. Estimated future cash expenditures are approximately $7.0 million. The company expects substantially all charges in the fiscal year ending September 30, 2027, and expects to substantially complete the actions by March 31, 2027, subject to applicable legal and employee notice and consultation requirements. It expects approximately $11.0 million in annualized cost savings once fully implemented. Actual charges, timing and savings may differ from estimates due to implementation matters.
Azenta, Inc. reported that 1,456 common shares were withheld from Interim CEO Martin D. Madaus on September 22, 2026, to satisfy tax withholding obligations arising from the vesting and settlement of 3,055 restricted stock units. The transaction was not a market sale. Madaus directly held 42,602 shares afterward, and no Rule 10b5-1 plan is reported.
Azenta, Inc. (AZTA) approved a new compensation package for Interim President and Chief Executive Officer Dr. Martin D. Madaus and granted retention equity awards to several named executive officers. Effective August 22, 2026, Dr. Madaus receives an annual base salary of $600,000 and a cash performance recognition bonus equal to 100% of his annual base salary in lieu of participation in the annual incentive plan. The bonus vests on the first anniversary of his start date or pro rata upon earlier termination, but is forfeited if employment ends for Cause or certain voluntary resignations, and any earned bonus is paid in a lump sum on January 1, 2028, subject to a release of claims. As of September 14, 2026, he also receives restricted stock units with an award value of $1,200,000, vesting in equal monthly installments over 12 months, determined using the 20-trading-day average closing price of the common stock. On September 11, 2026, the Human Resources and Compensation Committee approved one-time restricted stock unit retention awards for executives totaling $2.5 million in value, including $1,000,000 for CFO Lawrence Lin and $500,000 each for three other senior officers, with 50% vesting on each of the first and second anniversaries of the September 14, 2026 grant date and additional vesting protection upon certain terminations.
Azenta, Inc. (symbol: AZTA) is the issuer of record for a Form 4 filing submitted to the SEC. Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. (AZTA) reported that Interim CEO Martin D. Madaus received a grant of 36,653 restricted stock units under the company’s Equity Incentive Plan on September 14, 2026. No amount was paid for the grant, which vests 1/12 per month over twelve months and will settle in common stock, bringing his directly held shares to 44,058. No Rule 10b5-1 trading plan is reported for this award.
Azenta, Inc. (symbol: AZTA) is the issuer of record for a Form 4 filing submitted to the SEC. MARTIN WILLIAM E. III reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. (AZTA) reported that William E. Martin III, President Multiomics, received a grant of 15,272 shares of common stock in the form of restricted stock units on September 14, 2026 under the company’s Equity Incentive Plan, with no amount paid upon grant.
The restricted stock units are subject to time-based vesting and will vest 50% per year beginning on September 14, 2027, subject to the terms of the award agreement. Following this grant, Martin directly holds 33,062 shares of Azenta common stock.
Azenta, Inc. (symbol: AZTA) is the issuer of record for a Form 4 filing submitted to the SEC. Pirogova Olga reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. (AZTA) reported that Olga Pirogova, its Senior Vice President and Chief Human Resources Officer, received a grant of 15,272 shares of common stock in the form of restricted stock units under the company’s Equity Incentive Plan on September 14, 2026. No amount was paid for this grant, which is subject to time-based vesting and will vest 50% per year beginning on September 14, 2027, pursuant to the award terms. Following this award, she holds 47,225 shares of Azenta common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Azenta, Inc. (symbol: AZTA) is the issuer of record for a Form 4 filing submitted to the SEC. Lin Lawrence Y. reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. (AZTA) reported that Lawrence Y. Lin, EVP, CFO and Treasurer, received a grant of 30,544 restricted stock units of common stock on September 14, 2026 under the company’s Equity Incentive Plan. No amount was paid for this award, and it is payable solely in shares of common stock.
The units are subject to time-based vesting and will vest 50% per year beginning on September 14, 2027, under the terms of the award agreement. Following this grant, Lin holds 110,199 shares of Azenta common stock directly. No Rule 10b5-1 trading plan is reported for this transaction.
Azenta, Inc. (symbol: AZTA) is the issuer of record for a Form 4 filing submitted to the SEC. Starr Ephraim reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. (AZTA) reported that Ephraim Starr, its SVP, General Counsel and Secretary, received a grant of 15,272 restricted stock units of common stock on September 14, 2026 under the company’s Equity Incentive Plan. The award was granted at no cash cost to him and is subject to time-based vesting, with 50% vesting per year beginning on September 14, 2027. Following this grant, he holds 84,000 shares of Azenta common stock directly. No Rule 10b5-1 trading plan is reported in connection with this transaction.
Azenta, Inc. (symbol: AZTA) is the issuer of record for a Form 4 filing submitted to the SEC. Bello Erik J. reported acquisition or exercise transactions in this Form 4 filing.
Azenta, Inc. (AZTA) reported that Erik J. Bello, Vice President and Chief Accounting Officer, received a grant of 4,586 restricted stock units (RSUs) of common stock on September 15, 2026 under the company’s Equity Incentive Plan. No cash amount was paid upon grant, and the award is reported as directly owned.
The RSUs are subject to time-based vesting and will vest at a rate of 33-1/3% per year beginning on September 15, 2027, in accordance with the terms of the award agreement. Following this grant, Bello is reported as holding 4,586 shares/units of Azenta common stock directly.